NasdaqCM - Delayed Quote USD

FutureTech II Acquisition Corp. (FTIIW)

0.0440

+0.0230

+(109.52%)

At close: April 7 at 2:10:58 PM EDT

FutureTech II Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Reports on Form 10-Q and Publicly Held Shares Rule and Makes Progress Towards Regaining Compliance

New York, New York, Dec. 04, 2024 (GLOBE NEWSWIRE) -- FutureTech II Acquisition Corp. (the “Company”) (NASDAQ: FTII), today announced that it received an expected deficiency notification letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) on November 27, 2024 (the “Notice”). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended Sept

GlobeNewswire 5 months ago

FTII

FTIIU

FTIIW
+109.52%
Longevity Biomedical, Inc. and FutureTech II Acquisition Corp. Announce Business Combination to Create Nasdaq-Listed Biopharmaceutical Company Focused on Advancing New Technologies to Promote Human Health and Longevity

-Longevity Biomedical, Inc. is focused on developing and acquiring new technologies spanning therapeutics, health monitoring and digital health solutions to become a leading provider of longevity-related products and services designed to increase the health span for the rapidly growing global aging population. -Late-stage, diversified pipeline of therapeutic candidates across ophthalmology, cardiovascular disease and soft tissue reconstruction and repair. -Near-term clinical milestones include P

GlobeNewswire 7 months ago

FTII

FTIIU

FTIIW
+109.52%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

FutureTech II Acquisition Corp. (FTIIW)

FutureTech II Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Reports on Form 10-Q and Publicly Held Shares Rule and Makes Progress Towards Regaining Compliance

Longevity Biomedical, Inc. and FutureTech II Acquisition Corp. Announce Business Combination to Create Nasdaq-Listed Biopharmaceutical Company Focused on Advancing New Technologies to Promote Human Health and Longevity